---
canonical_name: Pterostilbene
alternate_names: trans-3,5-dimethoxy-4'-hydroxystilbene, trans-Pterostilbene, PT, PTER, pTeroPure, Pterostilbene (dimethylated resveratrol)
canonical_topic: Pterostilbene for Health & Longevity
short_topic_lc: pterostilbene
creation_date: 2026-0630-0211
creator_ai_fullname: Opus 4.8
---

# Pterostilbene for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 06/30/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** trans-3,5-dimethoxy-4'-hydroxystilbene, trans-Pterostilbene, PT, PTER, pTeroPure, Pterostilbene (dimethylated resveratrol)


## Motivation

<!-- This motivation section was written only after the rest of the document was completed, so that it accurately reflects the full scope of the topic. -->

Pterostilbene is a natural compound found in blueberries, grapes, and the heartwood of certain trees. It is closely related to resveratrol, the better-known compound in red wine, but carries two small chemical changes that let the body absorb it far more readily and keep it circulating longer. This has made it attractive to people interested in slowing aspects of aging, since in laboratory and animal work it switches on some of the same cellular housekeeping and stress-resistance pathways triggered by eating less.

Interest grew as researchers looked for a "better resveratrol" — a molecule with the same promise but without resveratrol's poor absorption. Pterostilbene has since been studied mainly for cholesterol and blood pressure, and is widely sold as a partner to nicotinamide riboside in cellular-energy supplements. A small human trial found it lowered blood pressure but, intriguingly, worsened one cholesterol marker when taken on its own.

This review examines what is actually known about pterostilbene: where the human evidence is solid, where it rests only on cells and animals, what the realistic benefits and risks appear to be, and how it is being used and studied as a longevity-oriented supplement.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level overviews and expert discussions that introduce pterostilbene and its longevity context for the general reader.

<!-- A real-time web search was performed across general search engines and the platforms of the priority experts (Rhonda Patrick/foundmyfitness.com, Peter Attia/peterattiamd.com, Andrew Huberman/hubermanlab.com, Chris Kresser/chriskresser.com, Life Extension/lifeextension.com). Rhonda Patrick has multiple items discussing pterostilbene by name in the NAD+/urolithin A context; one is listed below. Dedicated standalone pterostilbene overviews from Attia, Huberman, and Kresser were not found; Life Extension has relevant articles but its site blocks automated access for link verification, so verifiable longevity-focused overviews from Gowing Life and Lifespan.io were used instead, plus a qualifying narrative review. -->

* [A single dose of nicotinamide riboside & pterostilbene increased plasma NAD+ levels by 40% and a double dose by 90% after 4 weeks compared to placebo](https://www.foundmyfitness.com/stories/8dr06s/a_single_dose_of_nicotinamide_riboside_pterostilbene_increased_plasma_nad_levels_by_40_and_a_double_dose_by_90_after_4_weeks_compared_to_placebo) - Rhonda Patrick

  A plain-language research summary from Rhonda Patrick covering the first human trial of nicotinamide riboside plus pterostilbene, situating pterostilbene within the NAD+ (nicotinamide adenine dinucleotide, a coenzyme essential to energy metabolism) -boosting and longevity supplement landscape she discusses across FoundMyFitness.

* [Pterostilbene: A Longevity Supplement With Broad Protective Effects](https://www.gowinglife.com/pterostilbene-a-longevity-supplement-with-broad-protective-effects/) - Gowing Life

  A longevity-focused overview that explains why pterostilbene is considered a "better resveratrol," summarizing its absorption advantage and the breadth of preclinical protective effects relevant to aging.

* [Pterostilbene: Benefits, Side Effects, and Research](https://lifespan.io/topic/pterostilbene-benefits-side-effects/) - Lifespan.io

  A balanced reference that walks through pterostilbene's proposed mechanisms, the limited human data, and open questions, written for a longevity-oriented audience rather than as a product pitch.

* [A review of pterostilbene antioxidant activity and disease modification](https://pubmed.ncbi.nlm.nih.gov/23691264/) - McCormack & McFadden, 2013

  A widely cited narrative review mapping pterostilbene's antioxidant chemistry to disease pathways (cancer, neurological, vascular, metabolic), useful for understanding the mechanistic case that drives ongoing interest.

* [Metabolism and pharmacokinetics of resveratrol and pterostilbene](https://pubmed.ncbi.nlm.nih.gov/29315886/) - Wang & Sang, 2018

  A focused narrative review comparing how the body handles pterostilbene versus resveratrol, explaining the metabolic-stability and bioavailability differences that underpin pterostilbene's appeal.

Note on priority experts: Rhonda Patrick discusses pterostilbene by name (item above). No dedicated standalone pterostilbene overview from Peter Attia, Andrew Huberman, or Chris Kresser was found; Life Extension has relevant articles, but its site blocks automated access for link verification, so verifiable longevity-focused overviews from Gowing Life and Lifespan.io were used instead.


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "Pterostilbene"; a dedicated article exists at the page below. -->

* [Pterostilbene](https://grokipedia.com/page/Pterostilbene) - Grokipedia

  A general reference entry covering pterostilbene's chemistry, dietary sources, mechanisms, and research status, useful as a broad orientation before consulting primary sources.


## Examine

<!-- examine.com was searched directly using the browser tool for "Pterostilbene"; a dedicated, evidence-graded supplement page exists at the URL below. -->

* [Pterostilbene](https://examine.com/supplements/pterostilbene/) - Examine

  Examine's independent, evidence-graded summary notes that only a small amount of human data exists, flags the LDL ("bad" cholesterol) increase and blood-pressure decrease seen in the single metabolic trial, and provides dosing context derived from animal studies.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "Pterostilbene". No dedicated pterostilbene review or product test was found; ConsumerLab covers the related compound resveratrol but has not published a standalone pterostilbene review. -->

No dedicated ConsumerLab review or product test for pterostilbene was found.


## Systematic Reviews

A real-time PubMed search for systematic reviews and meta-analyses of pterostilbene returned almost no human-outcome syntheses; the single qualifying meta-analysis evaluates preclinical (animal) data, reflecting how thin the controlled human evidence base remains.

* [The effect of pterostilbene and its active ingredients on experimental pulmonary fibrosis in asthma: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36457679/) - Peng et al., 2022

  A meta-analysis of seven randomized animal experiments (62 subjects total) finding pterostilbene up-regulated antioxidant defenses (superoxide dismutase, glutathione) and lowered the oxidative-damage marker malondialdehyde; the evidence is entirely preclinical and not directly applicable to humans.

<!-- No systematic review or meta-analysis of pterostilbene measuring human clinical outcomes (cardiometabolic, cognitive, longevity, or otherwise) was identified. The only meta-analysis indexed pools animal studies. This scarcity is itself an important finding about the maturity of the evidence base. -->


## Mechanism of Action

Pterostilbene is a stilbene — a small plant compound built from two benzene rings joined by a two-carbon bridge — and is the dimethylated cousin of resveratrol. Replacing two hydroxyl groups with methoxy groups makes pterostilbene more fat-soluble, which is the structural reason it crosses cell membranes and is absorbed more efficiently.

Its proposed longevity-relevant actions cluster around a few overlapping pathways:

* **Antioxidant and anti-inflammatory signaling.** Pterostilbene activates Nrf2 (a master switch that turns on the cell's own antioxidant defenses) and suppresses NF-κB (a central controller of inflammatory gene expression), reducing reactive oxygen species (unstable oxygen molecules that damage cells) in numerous models.

* **Sirtuin and AMPK activation.** Like resveratrol, pterostilbene is described as a sirtuin-activating compound — sirtuins (SIRT1 in particular) are enzymes that help coordinate the cellular response to low-energy, "calorie-restriction-like" states. It also activates AMPK (AMP-activated protein kinase, a fuel-sensing enzyme that promotes energy production and cellular cleanup), and can dampen mTOR (mechanistic target of rapamycin, a growth-signaling pathway whose suppression is linked to longevity).

* **NAD+ context.** In its most common supplement form, pterostilbene is paired with nicotinamide riboside, a precursor to NAD+ (which is also essential to sirtuin activity); pterostilbene is included partly to complement sirtuin signaling.

Competing interpretations exist. Critics note that many sirtuin- and AMPK-activating effects were demonstrated at concentrations far above what oral dosing achieves in blood, and that some "direct sirtuin activation" findings for the stilbene class have been challenged as artifacts of the laboratory assay rather than true cellular effects. The mechanistic case is therefore best read as plausible and partially supported, not settled.

As a pharmacological compound, pterostilbene's key properties are: an oral bioavailability of roughly 80% in animal models (versus about 20% for resveratrol), a plasma half-life on the order of a few hours (commonly cited near 105 minutes in rodents), wide tissue distribution owing to its lipophilicity, and metabolism primarily by glucuronidation and sulfation via UGT enzymes (UGT1A1/UGT1A3, which attach water-soluble groups to aid excretion), with comparatively slower conjugation than resveratrol contributing to its greater metabolic stability.


## Historical Context & Evolution

Pterostilbene was first identified in plants decades ago and is naturally produced as a phytoalexin — a defensive compound plants make in response to stress or infection — notably in the heartwood of red sandalwood (*Pterocarpus* species, the source of its name) and in blueberries and grapes. Its original "use," in the natural sense, was as part of the plant's own antimicrobial defense.

Scientific interest in pterostilbene for human health grew out of the resveratrol story. After resveratrol became famous as a proposed mediator of the "French paradox" and a calorie-restriction mimic, researchers searching for analogs with better absorption turned to pterostilbene, which delivers similar signaling with markedly higher bioavailability. Early-2000s work on its cholesterol-lowering receptor activity (PPAR-α, a regulator of fat metabolism) and antioxidant chemistry positioned it as a candidate for cardiometabolic and longevity applications.

The actual findings that built the case were largely preclinical: cell and rodent studies showing antioxidant, anti-inflammatory, anticancer, neuroprotective, and metabolic effects. The first dedicated human trial (a cardiometabolic study) appeared in the mid-2010s, and the compound later gained visibility as the stilbene component of commercial nicotinamide riboside supplements.

Scientific opinion has evolved toward cautious interest rather than endorsement. The early enthusiasm grounded in mechanism has been tempered by the recognition that human outcome data remain scarce and that a key human trial showed an unexpected LDL-cholesterol increase. What changed is not that pterostilbene was "disproven," but that the field now distinguishes clearly between robust preclinical signals and the still-limited controlled human evidence — leaving its real-world longevity value genuinely open.


## Expected Benefits

A dedicated search of clinical trials, expert sources, and the mechanistic literature was performed to assemble a complete benefit profile. The defining feature of pterostilbene's benefit map is that nearly all of it rests on preclinical data; the few human findings are concentrated in cardiometabolic measures.

### High 🟩 🟩 🟩

(No benefits qualify for a High evidence grade. No benefit has been confirmed by multiple high-quality human randomized trials or meta-analyses of human outcomes.)

### Medium 🟩 🟩

#### Blood Pressure Reduction

In the single dedicated human cardiometabolic trial, the higher pterostilbene dose lowered both systolic and diastolic blood pressure versus placebo, an effect consistent with stilbene-class vasodilatory and antioxidant actions on the blood-vessel lining. The evidence basis is one randomized, double-blind, placebo-controlled trial in 80 adults with elevated cholesterol, supported by Examine's independent grading of a small blood-pressure improvement. The effect was seen at the 250 mg/day dose but not clearly at 100 mg/day, and the trial was short (6–8 weeks) and not designed primarily around blood pressure, so the finding is promising but not yet replicated.

**Magnitude:** Approximately −7.8 mmHg systolic and −7.3 mmHg diastolic at 250 mg/day versus placebo over 6–8 weeks.

### Low 🟩

#### Improved Cellular Energy / NAD+ Support (as part of nicotinamide riboside combination)

When combined with nicotinamide riboside, pterostilbene is part of a regimen shown to raise blood NAD+ — a coenzyme central to energy metabolism that declines with age. The mechanistic rationale is that pterostilbene complements sirtuin signaling while nicotinamide riboside supplies NAD+ precursor; the evidence basis is human trials of the combination (not pterostilbene alone), so the specific contribution of pterostilbene to any clinical benefit cannot be isolated. Notably, the key combination trials were funded and largely conducted by Elysium Health, the manufacturer of the "Basis" product — a direct financial conflict of interest that warrants caution in weighing these results. NAD+ elevation is a biomarker change, not a demonstrated health outcome.

**Magnitude:** The combination raised whole-blood NAD+ by roughly 40% (standard dose) to 90% (double dose) versus placebo; pterostilbene's independent contribution is not quantified.

#### Reduced Markers of Liver Inflammation (combination, fatty liver)

In adults with non-alcoholic fatty liver disease, the nicotinamide riboside–pterostilbene combination at the recommended dose significantly lowered the liver enzymes ALT (alanine aminotransferase) and GGT (gamma-glutamyltransferase) and a toxic lipid (a ceramide), though it did not change the primary endpoint of liver fat. The evidence basis is one 6-month randomized, placebo-controlled trial of the combination, so again pterostilbene's standalone role is unclear, and the changes were in markers rather than hard clinical endpoints.

**Magnitude:** Statistically significant time-dependent reductions in ALT and GGT versus placebo; absolute values modest and not consistently dose-dependent.

#### Antioxidant Capacity / Oxidative-Stress Reduction

Pterostilbene reproducibly raises antioxidant defenses and lowers oxidative-damage markers across many models, and a meta-analysis of animal studies confirmed increased superoxide dismutase and glutathione with reduced malondialdehyde. The evidence basis is strong mechanistically and in animals but thin in humans, where direct measurement of pterostilbene's antioxidant effect on clinical outcomes is lacking. This underlies much of the broader longevity rationale.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Cognitive and Mood Benefits

Pterostilbene has shown neuroprotective and anti-anxiety effects in rodent models, with interest in memory, learning, and age-related cognitive decline. No controlled human trials confirm a cognitive or mood benefit; the basis is mechanistic and animal data only, and notably the anti-anxiety effect in mice appeared at low doses with a possible loss of effect at higher doses, complicating translation.

#### Anticancer / Chemopreventive Activity

Pterostilbene triggers programmed cell death, cell-cycle arrest, and anti-metastatic effects across numerous cancer cell lines and animal tumor models, and is being formally tested in an endometrial cancer trial. In humans this remains unproven for prevention or treatment; the basis is extensive preclinical work plus an early-phase safety/biomarker trial, not efficacy data.

#### Blood Sugar and Lipid Metabolism Improvement

Animal studies report improved insulin sensitivity, lower blood glucose, and favorable lipid changes via PPAR-α activation. Human evidence is absent or conflicting — the one human metabolic trial found minor weight loss in those not on cholesterol medication but, critically, raised LDL cholesterol rather than improving the lipid profile, so any metabolic benefit in humans is speculative and possibly offset.

#### General Healthspan / Longevity Extension

Pterostilbene extended mean lifespan in fruit flies and engages calorie-restriction-associated pathways, fueling its use as a longevity supplement. There is no human longevity or healthspan outcome data; the basis is invertebrate lifespan studies and mechanism, making any longevity claim purely speculative at present.


## Benefit-Modifying Factors

* **Genetic polymorphisms (UGT enzymes):** Variation in UGT1A1/UGT1A3 (enzymes that conjugate and clear pterostilbene) could in principle raise or lower circulating levels and thus the size of any benefit; faster-clearing genotypes might blunt the blood-pressure and antioxidant signals, though no pharmacogenetic data exist for pterostilbene in humans.

* **Baseline cardiometabolic status:** The clearest human signal (blood-pressure lowering) was observed in adults with elevated cholesterol; those with already-optimal blood pressure may see little change, and benefit is most plausible where there is room to improve.

* **Concurrent cholesterol medication:** In the human trial, being on a baseline cholesterol-lowering drug appeared to attenuate pterostilbene's effects on LDL, suggesting medication status modifies the lipid response.

* **Co-administration with grape extract:** Adding grape extract to low-dose pterostilbene blunted the LDL increase seen with pterostilbene alone, indicating that the formulation (isolated versus combined with other polyphenols) modifies the net metabolic effect.

* **Gut microbiome composition:** Pterostilbene has been linked to enhanced conversion of dietary precursors to urolithin A (a gut-bacteria-derived compound that supports mitochondrial cleanup); since the capacity to produce urolithin A varies widely between people and declines with age, microbiome status may modify downstream benefits.

* **Sex-based differences:** In fruit-fly lifespan work, pterostilbene extended lifespan in both sexes but more strongly in females, and modulated different proteins by sex; whether any sex-based difference exists in humans is unknown.

* **Age:** Because several proposed benefits (NAD+ support, urolithin A conversion, antioxidant defense) target processes that decline with age, older adults within the target audience are hypothesized to have more to gain, though this is not directly demonstrated.


## Potential Risks & Side Effects

A dedicated search of the human safety trial, drug-interaction references, and the mechanistic literature was performed to assemble a complete risk profile. Human safety data come almost entirely from one dedicated safety analysis and from combination-product trials; the standout concern is an LDL-cholesterol increase.

### High 🟥 🟥 🟥

(No risks qualify for a High evidence grade based on multiple high-quality human trials.)

### Medium 🟥 🟥

#### Increased LDL ("Bad") Cholesterol

In the dedicated human metabolic trial, pterostilbene taken on its own raised LDL cholesterol, an unexpected and clinically relevant effect for a longevity-oriented audience focused on cardiovascular risk. The proposed mechanism is unclear but the effect was dose-related, was not seen when low-dose pterostilbene was combined with grape extract, and appeared attenuated in those already on cholesterol medication. The evidence basis is one randomized, double-blind, placebo-controlled trial in 80 adults; Examine independently grades the LDL increase as a real signal from this study.

**Magnitude:** LDL increased by approximately 17 mg/dL with pterostilbene monotherapy versus placebo over 6–8 weeks.

### Low 🟥

#### Generally Mild, Non-Serious Adverse Events

The dedicated human safety trial found pterostilbene generally safe up to 250 mg/day, with no statistically significant adverse effects on liver, kidney, or glucose markers and no serious self-reported reactions over 6–8 weeks. The evidence basis is that single safety-focused randomized trial plus safety data from combination-product studies; the main limitations are short duration, small numbers, and lack of long-term human data. Mild gastrointestinal complaints are occasionally reported anecdotally.

**Magnitude:** No statistically significant excess of adverse events versus placebo at doses up to 250 mg/day.

### Speculative 🟨

#### Drug-Metabolism (CYP/UGT) Interactions

As a polyphenol metabolized by and potentially modulating glucuronidation and cytochrome P450 enzymes, pterostilbene could theoretically alter blood levels of co-administered drugs. No clinically significant human interaction has been documented; the concern is mechanistic and extrapolated from the broader stilbene/polyphenol class.

#### Additive Blood-Pressure Lowering

Given pterostilbene's blood-pressure-lowering signal, combining it with antihypertensive drugs or other blood-pressure-lowering supplements could theoretically cause excessive drops. This is a plausible additive effect rather than a documented adverse event in trials.

#### Effects in Pregnancy and Breastfeeding

Pterostilbene has hormone-pathway and cell-signaling activity in preclinical models, and safety in pregnancy or lactation has not been studied. Avoidance in these states is a precautionary inference, not a finding of harm.

#### Pro-oxidant or Hormetic Effects at High Doses

Some polyphenols, antioxidant at typical doses, can behave as pro-oxidants at high concentrations, and pterostilbene's anti-anxiety effect in mice was lost at higher doses, hinting at a dose-response that is not simply "more is better." Whether high human doses carry risk is unknown and untested.


## Risk-Modifying Factors

* **Genetic polymorphisms (UGT enzymes):** Variation in UGT1A1/UGT1A3 (enzymes that conjugate and clear pterostilbene) could in principle affect blood levels and thus both effect size and risk, though no pharmacogenetic dosing data exist for pterostilbene in humans.

* **Baseline lipid levels and cardiovascular risk:** Because the documented risk is an LDL increase, individuals with already-elevated LDL or established cardiovascular disease stand to be most affected and have the most to lose from monotherapy.

* **Sex-based differences:** No human data establish sex differences in pterostilbene's risk profile; preclinical lifespan studies show sex-specific protein responses, leaving the possibility open but unconfirmed.

* **Pre-existing conditions:** Those with cardiovascular disease, lipid disorders, or on multiple medications metabolized by glucuronidation/CYP pathways warrant more caution, primarily because of the LDL signal and theoretical interactions.

* **Age:** Older adults may metabolize and clear the compound differently and are more likely to be on interacting cardiovascular medications, modestly raising the relevance of the LDL and interaction concerns.

* **Concurrent medications and supplements:** Use alongside antihypertensives or other blood-pressure-lowering agents may amplify blood-pressure effects, and combination with other polyphenols (e.g., grape extract) appears to alter the lipid response.


## Key Interactions & Contraindications

* **Antihypertensive drugs:** Combining pterostilbene with blood-pressure-lowering medications (ACE inhibitors such as lisinopril, ARBs [angiotensin receptor blockers] such as losartan, calcium channel blockers such as amlodipine, diuretics) could have an additive effect. Severity: caution/monitor. Clinical consequence: excessive blood-pressure lowering (hypotension — abnormally low blood pressure causing dizziness or fainting). Mitigation: monitor blood pressure when starting.

* **Lipid-lowering drugs (statins, ezetimibe):** Because pterostilbene monotherapy can raise LDL, it may partially work against cholesterol-lowering therapy; conversely, statin use appeared to attenuate pterostilbene's LDL effect in trial data. Severity: caution/monitor. Clinical consequence: altered LDL response. Mitigation: check a lipid panel after starting.

* **Over-the-counter agents:** No specific OTC drug interaction is documented. Theoretically, combining with OTC products that affect blood pressure (e.g., decongestants such as pseudoephedrine, which raise blood pressure) could blunt or complicate the blood-pressure effect. Severity: caution. Mitigation: monitor if used together.

* **Blood-pressure-lowering supplements (additive effects):** Supplements that also lower blood pressure — such as beetroot/nitrate, magnesium, garlic extract, omega-3 fish oil, and CoQ10 (coenzyme Q10, an antioxidant involved in cellular energy) — may add to pterostilbene's blood-pressure effect. Severity: caution/monitor. Clinical consequence: additive hypotension. Mitigation: introduce one change at a time and monitor.

* **Other polyphenol supplements (resveratrol, grape extract):** Co-use with resveratrol or grape extract changes the net effect; grape extract specifically blunted the LDL increase. Severity: generally favorable/monitor. Mitigation: consider combined formulations if LDL is a concern.

* **Drugs with narrow therapeutic windows metabolized by glucuronidation/CYP:** Theoretical interaction with agents cleared by UGT or CYP pathways (CYP3A4 substrates such as certain statins, immunosuppressants, some benzodiazepines). Severity: theoretical caution. Mitigation: monitor where the co-drug requires tight control.

* **Other interventions:** As an antioxidant, pterostilbene could theoretically interact with treatments whose mechanism relies on oxidative stress (e.g., certain chemotherapy or radiotherapy); relevance is unproven but a reason for oncology patients to coordinate with their team.

* **Populations who should avoid or use caution:** Pregnant or breastfeeding individuals (no safety data); people with high or poorly controlled LDL cholesterol or established cardiovascular disease (recent myocardial infarction [heart attack] within 90 days, or NYHA Class III–IV heart failure) given the LDL signal; those on multiple interacting medications; and anyone with significant liver impairment (Child-Pugh Class C, i.e., severe liver dysfunction) given reliance on hepatic metabolism.


## Risk Mitigation Strategies

* **Monitor a lipid panel before and after starting:** Because the best-documented risk is an LDL increase, checking LDL at baseline and again at 6–12 weeks lets a rise be caught early; this mitigates undetected worsening of cardiovascular risk.

* **Prefer combined formulations when LDL is a concern:** Using pterostilbene combined with grape extract or other polyphenols, rather than high-dose isolated pterostilbene, addresses the LDL increase, which was blunted by grape extract in trial data.

* **Keep the dose modest (≤250 mg/day):** Staying at or below the dose shown to be generally safe in the human safety trial (250 mg/day) mitigates the risk of unknown high-dose effects and the dose-related LDL rise, which were more pronounced at higher intakes.

* **Monitor blood pressure when combining with blood-pressure-lowering agents:** Checking blood pressure after starting, especially alongside antihypertensives or blood-pressure-lowering supplements, mitigates additive hypotension.

* **Separate timing or coordinate with narrow-window medications:** For anyone on drugs requiring tight blood-level control (e.g., immunosuppressants, certain statins), spacing dosing and reviewing the regimen with a clinician mitigates the theoretical metabolism-based interaction.

* **Avoid during pregnancy and breastfeeding:** Refraining from use when pregnant or nursing mitigates the unquantified risk arising from the complete absence of safety data in these states.


## Therapeutic Protocol

* **Standard dose range:** Leading practitioner usage and the human safety/efficacy trials center on 50–250 mg/day of isolated pterostilbene, with 250 mg/day being the highest dose shown to be generally safe over 6–8 weeks. Many longevity-oriented users take 50–150 mg/day.

* **Combination approaches (without framing one as default):** Two main approaches are used. (1) Isolated pterostilbene, favored by those targeting the cardiometabolic and antioxidant signals directly. (2) Pterostilbene paired with nicotinamide riboside (the most widely marketed form, popularized by Elysium Health's "Basis," developed with MIT's Leonard Guarente), which delivers pterostilbene at roughly 50 mg alongside 250–500 mg nicotinamide riboside and is favored by those targeting NAD+ support. A grape-extract pairing is a third option specifically to offset the LDL effect.

* **Best time of day:** No clear chronobiological optimum is established; it is commonly taken with a morning meal. Taking it with food containing some fat is reasonable given its fat-soluble nature.

* **Half-life and dosing frequency:** With a plasma half-life on the order of a few hours, twice-daily dosing was used in the human trials (e.g., 125 mg twice daily) and is a reasonable way to maintain levels; once-daily dosing is common in practice for convenience.

* **Single versus split doses:** The pivotal human trials used split (twice-daily) dosing. Splitting may smooth blood levels given the short half-life, while once-daily is acceptable for general supplementation.

* **Genetic polymorphisms:** No validated pharmacogenetic guidance exists; UGT1A1/UGT1A3 variation could theoretically affect clearance, but there is no basis for genotype-guided dosing.

* **Sex-based differences:** Human dosing has not been differentiated by sex; preclinical lifespan data hint at sex-specific responses, but no human protocol adjustment is supported.

* **Age-related considerations:** Older adults, more likely to be on cardiovascular medications, warrant the same modest dosing plus lipid and blood-pressure monitoring; no age-specific dose is established.

* **Baseline biomarkers:** Baseline LDL and blood pressure are the most useful pre-treatment measures, both to identify who may benefit (elevated blood pressure) and who is most exposed to the LDL risk.

* **Pre-existing conditions:** Those with lipid disorders or cardiovascular disease should weigh the LDL signal and favor monitored, combination, or lower-dose approaches.


## Discontinuation & Cycling

* **Lifelong versus short-term:** Pterostilbene is used as an ongoing supplement rather than a defined course; there is no established treatment duration, and human data extend only to a few weeks to six months.

* **Withdrawal effects:** No withdrawal syndrome or rebound effect has been reported on stopping pterostilbene; effects such as blood-pressure or LDL changes would be expected to simply reverse as the compound clears.

* **Tapering:** No taper is needed given the absence of withdrawal effects; it can reasonably be stopped abruptly.

* **Cycling:** No evidence indicates that cycling improves efficacy or is necessary. Some users cycle polyphenol supplements on general principle, but there is no pterostilbene-specific rationale or data supporting cycling for maintained effect.

* **Practical discontinuation point:** A reasonable reason to discontinue is a confirmed meaningful LDL increase on follow-up testing, after which stopping (and rechecking lipids) is the straightforward response.


## Sourcing and Quality

* **Form and purity:** Look for trans-pterostilbene of high stated purity (often ≥99%). The trans isomer is the studied, active form; reputable products specify it.

* **Third-party testing:** Because supplements are not tightly regulated, prefer products with third-party testing or certification (e.g., NSF, USP, or a published certificate of analysis) verifying identity, potency, and absence of contaminants.

* **Standardized branded ingredients:** A widely used standardized material is pTeroPure (originally ChromaDex), a synthetic, nature-identical trans-pterostilbene used in many commercial products; branded ingredients add some assurance of consistency.

* **Reputable brands and formulations:** Established longevity-supplement brands and the nicotinamide riboside–pterostilbene combination products (e.g., Elysium's Basis) are commonly cited; for isolated pterostilbene, choose brands that publish testing. Compounding is generally unnecessary as quality consumer products exist.

* **Storage and stability:** Store away from heat, light, and moisture; pterostilbene is reasonably stable but, like other polyphenols, benefits from a cool, dark, dry environment.


## Practical Considerations

* **Time to effect:** Cardiometabolic effects (blood pressure, LDL) in the human trial emerged over 6–8 weeks, so several weeks of consistent use are needed before reassessing biomarkers; no acute, perceptible effect should be expected.

* **Common pitfalls:** Assuming pterostilbene behaves like a pure "cholesterol-lowering" polyphenol (it raised LDL as monotherapy in humans); conflating combination-product (nicotinamide riboside plus pterostilbene) results with pterostilbene alone; using high doses on the belief that more is better despite a possible bell-shaped dose-response; and extrapolating strong animal results directly to humans.

* **Regulatory status:** Pterostilbene is sold as a dietary supplement (not an approved drug) and has been the subject of a self-affirmed GRAS (generally recognized as safe) determination for food use; it is not FDA-approved to treat any condition, and any therapeutic use is off-label/self-directed.

* **Cost and accessibility:** Isolated pterostilbene is widely available and relatively inexpensive; branded nicotinamide riboside–pterostilbene combination products are considerably more expensive, which is a practical consideration when the standalone evidence for pterostilbene is limited.

* **Realistic expectations:** It is best viewed as an experimental, mechanistically promising longevity supplement with limited human outcome data — not an established therapy.


## Interaction with Foundational Habits

* **Sleep:** The interaction is largely indirect and unstudied in humans. No evidence shows pterostilbene disrupts or improves sleep; its NAD+/sirtuin-related mechanisms touch circadian biology in theory, but there is no practical sleep-timing recommendation. Direction: none/indirect.

* **Nutrition:** Direction: direct and potentiating. Because pterostilbene is fat-soluble, taking it with a meal containing some fat plausibly aids absorption. It occurs naturally in blueberries and grapes, so a polyphenol-rich diet provides small background amounts; pairing with other dietary polyphenols (e.g., grape extract) altered its lipid effect in trial data, a practical reason to consider food/formulation context.

* **Exercise:** Direction: potentially potentiating but unproven. As an antioxidant, high-dose pterostilbene shares the theoretical concern raised for antioxidant supplements of possibly blunting some exercise-induced adaptations, though this has not been demonstrated for pterostilbene; an ongoing trial is examining its effect on exercise-induced oxidative stress. No specific workout-timing guidance is established.

* **Stress management:** Direction: indirect, possibly favorable. Rodent studies suggest anti-anxiety effects and modulation of stress-related oxidative pathways, but no human data confirm an effect on cortisol (the main stress hormone) or perceived stress; any benefit here is speculative and not a reason to use it for stress.


## Monitoring Protocol & Defining Success

Baseline testing before starting pterostilbene should focus on the parameters the human evidence flags as most relevant — lipids and blood pressure — so that both potential benefit and the main documented risk can be tracked objectively.

Ongoing monitoring is reasonable at 6–12 weeks after starting (to capture the timeframe over which trial effects appeared), then every 6–12 months with continued use, with more frequent lipid checks if a rise is detected or if cardiovascular risk is a concern.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| LDL cholesterol | < 100 mg/dL (lower for high CV risk) | Detects the main documented risk: pterostilbene monotherapy can raise LDL | CV = cardiovascular (heart and blood-vessel). Fasting 9–12 h preferred; conventional "high" threshold is ≥130 mg/dL, but functional targets are lower; recheck at 6–12 weeks |
| Total & HDL cholesterol, triglycerides | HDL > 50 mg/dL; triglycerides < 100 mg/dL | Provides full lipid context; a downward HDL trend was hinted at in human data | HDL = high-density lipoprotein ("good" cholesterol). Part of the same fasting lipid panel; assess alongside LDL |
| Blood pressure | < 120/80 mmHg | Tracks the main potential benefit and guards against additive hypotension | Measure seated, rested; average multiple readings; monitor if combined with BP-lowering agents |
| Fasting glucose / HbA1c | Glucose 70–90 mg/dL; HbA1c < 5.4% | Screens for metabolic effects given mixed preclinical glucose findings | HbA1c = glycated hemoglobin, a marker of average blood sugar. Fasting for glucose; HbA1c reflects ~3-month average and needs no fasting |
| ALT & GGT (liver enzymes) | ALT < 25 U/L (men) / < 20 U/L (women); GGT low-normal | Liver enzymes both signal safety and were the markers improved by the combination product | No fasting required; useful if using the nicotinamide riboside combination |

Qualitative markers worth tracking subjectively:

* Energy levels and exercise tolerance
* Cognitive clarity and mood
* General sense of wellbeing
* Any new symptoms (e.g., lightheadedness suggesting low blood pressure)

Success is best defined as stable or improved blood pressure and metabolic markers with no adverse rise in LDL, rather than any acute felt effect.


## Emerging Research

Research is moving from preclinical work toward human trials, increasingly testing pterostilbene within combinations and in specific disease and aging contexts. The directions below include studies that could strengthen the case (healthspan, antioxidant, NAD+ support) and those that could weaken or complicate it (cancer efficacy, neutral muscle/regeneration findings).

* **Combination gerotherapeutics for healthspan:** A Phase 3 trial sponsored by AgelessRx ([NCT07475546](https://clinicaltrials.gov/study/NCT07475546), enrollment 30) is testing combination longevity interventions with healthspan endpoints including VO₂ max (a measure of cardiorespiratory fitness), cognitive performance, an inflammation index, and lean body mass — directly relevant to the longevity rationale for stilbenes.

* **Endometrial cancer (chemoprevention/biomarker):** A Phase 2 trial ([NCT03671811](https://clinicaltrials.gov/study/NCT03671811), enrollment 44, City of Hope) tests megestrol acetate with or without pterostilbene, with tumor proliferation (Ki-67) as the primary endpoint; an associated review reports it confirmed safety and showed modulation of immune-related gene expression and mTOR signaling.

* **ALS (nicotinamide riboside–pterostilbene):** The NO-ALS program ([NCT04562831](https://clinicaltrials.gov/study/NCT04562831), enrollment 380) and its extension ([NCT05095571](https://clinicaltrials.gov/study/NCT05095571), enrollment 300) test the combination on disease progression and safety in amyotrophic lateral sclerosis (a progressive nerve-and-muscle wasting disease), a key real-world test of the NAD+-supporting combination.

* **Exercise-induced oxidative stress:** A trial ([NCT07024966](https://clinicaltrials.gov/study/NCT07024966), enrollment 14, Eurecat) tests a pterostilbene cocrystal with silybin and nicotinamide riboside on the oxidative-stress marker malondialdehyde during exercise — relevant to both the antioxidant benefit case and the concern that antioxidants might blunt exercise adaptations.

* **Bioavailability formulation work:** Completed pharmacokinetic studies of a pterostilbene cocrystal versus the free form ([NCT05561075](https://clinicaltrials.gov/study/NCT05561075); [NCT06289140](https://clinicaltrials.gov/study/NCT06289140), Eurecat) address the practical question of improving absorption, which could change effective dosing.

* **Future directions that could weaken the case:** Published combination trials in elderly muscle regeneration found no benefit of nicotinamide riboside plus pterostilbene on muscle recovery (Jensen et al., 2022, [PMID 35998039](https://pubmed.ncbi.nlm.nih.gov/35998039/)), and the NAFLD trial missed its primary liver-fat endpoint (Dellinger et al., 2023, [PMID 36082508](https://pubmed.ncbi.nlm.nih.gov/36082508/)) — reminders that several human endpoints have been neutral.

* **Key unanswered question:** The most important gap is a dedicated, adequately powered human trial of pterostilbene alone with hard cardiovascular or longevity endpoints, which would resolve whether the favorable blood-pressure signal and the unfavorable LDL signal net to benefit or harm.


## Conclusion

Pterostilbene is a blueberry-derived compound closely related to resveratrol but absorbed far more efficiently, which is the main reason it has drawn interest as a longevity supplement. In the laboratory and in animals it switches on cellular defense and energy-sensing systems linked to the benefits of eating less, and it reliably strengthens the body's antioxidant defenses. That mechanistic promise is broad, spanning heart, metabolic, brain, and anti-cancer effects.

The human picture is far thinner and more mixed. A single dedicated trial found that pterostilbene lowered blood pressure but unexpectedly raised "bad" LDL cholesterol when taken on its own — an important caveat for anyone focused on heart health. Most other human work tests it combined with another compound, so pterostilbene's own contribution is hard to isolate, and several of those combination results were neutral. It appears generally well tolerated at typical doses over short periods.

Overall, pterostilbene sits in the category of mechanistically interesting but clinically unproven. The evidence base is dominated by cell and animal studies, while the human evidence is limited to a handful of small, short trials — several of the most prominent of which were funded by the company that sells the leading combination product, a conflict of interest worth keeping in mind. The unresolved tension between its blood-pressure benefit and its cholesterol drawback captures the genuine uncertainty that defines what is currently known.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**